+ Watch MNKD
on My Watchlist
A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.
I think MannKind is a very risky investment. It's key inhalable insulin product, Afrezza, has been rejected by the FDA twice and won't be approved before 2013. It has been relying on its CEO for cash injections and had major job cuts last year. Its financial status is fragile to say the least. As a scientist, I would love to see Afrezza hit the market and provide diabetics with an additional option. As an investor, this is just too risky for me.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions